Tosufloxacin tosylate hydrate A-61827 tosylate hydrate; T-3262|cas:1400591-39-0|西域试剂

Tosufloxacin tosylate hydrate A-61827 tosylate hydrate; T-3262,99.03%

产品编号：Bellancom-B1802A| CAS NO：1400591-39-0| 分子式：C₂₆H₂₅F₃N₄O₇S| 分子量：594.56

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-B1802A	￥500.00	杭州北京（现货）
Bellancom-B1802A	￥900.00	杭州北京（现货）
Bellancom-B1802A	￥1500.00	杭州北京（现货）
Bellancom-B1802A	￥2000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Tosufloxacin tosylate hydrate A-61827 tosylate hydrate; T-3262

产品介绍

Tosufloxacin (A-61827) tosylate hydrate 是一种具有口服活性的氟喹诺酮类抗生素。Tosufloxacin 对革兰氏阳性和革兰氏阴性细菌表现出广泛的抗菌活性。

生物活性

Tosufloxacin tosylate hydrate (A-61827) is an orally active fluoroquinolone antibiotic. Tosufloxacin shows a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria.

体外研究

Tosufloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) shows antibacterial activities against S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	S. aureus, Staphylococcus epidermidis, streptococci, enterococci, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens
Concentration:	0.05-3.13 μg/mL
Incubation Time:	18 hours
Result:	Showed MIC₉₀s (MICs for 90% of the isolates tested) ranging from 0.05 to 1.56 μg/mL for S. aureus, Staphylococcus epidermidis, streptococci, and enterococci. Showed MIC₉₀s of 1.56, 3.13, and 0.20 μg/mL for Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens, respectively.

体内研究
(In Vivo)

Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Slc:ICR mice infected with S. aureus
Dosage:	1.27-2.15 mg/kg
Administration:	Oral gavage; 1.27-2.15 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 1.62 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with E. coli
Dosage:	0.16-0.30 mg/kg
Administration:	Oral gavage; 0.16-0.30 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 0.22 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with P. aeruginosa
Dosage:	7.66-13.39 mg/kg
Administration:	Oral gavage; 7.66-13.39 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 10.13 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.78 μg/mL.

体内研究

Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Slc:ICR mice infected with S. aureus
Dosage:	1.27-2.15 mg/kg
Administration:	Oral gavage; 1.27-2.15 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 1.62 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with E. coli
Dosage:	0.16-0.30 mg/kg
Administration:	Oral gavage; 0.16-0.30 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 0.22 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with P. aeruginosa
Dosage:	7.66-13.39 mg/kg
Administration:	Oral gavage; 7.66-13.39 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 10.13 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.78 μg/mL.

体内研究

Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Slc:ICR mice infected with S. aureus
Dosage:	1.27-2.15 mg/kg
Administration:	Oral gavage; 1.27-2.15 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 1.62 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with E. coli
Dosage:	0.16-0.30 mg/kg
Administration:	Oral gavage; 0.16-0.30 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 0.22 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL.

Animal Model:	Male Slc:ICR mice infected with P. aeruginosa
Dosage:	7.66-13.39 mg/kg
Administration:	Oral gavage; 7.66-13.39 mg/kg; once
Result:	Showed 50% effective dose (ED₅₀) of 10.13 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.78 μg/mL.

性状

Solid

溶解性数据

In Vitro:

DMSO : 12.5 mg/mL (21.02 mM; Need ultrasonic)

H₂O : 1 mg/mL (1.68 mM; ultrasonic and warming and heat to 80°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6819 mL	8.4096 mL	16.8192 mL
5 mM	0.3364 mL	1.6819 mL	3.3638 mL
10 mM	0.1682 mL	0.8410 mL	1.6819 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1.25 mg/mL (2.10 mM); Suspended solution; Need ultrasonic

此方案可获得 1.25 mg/mL (2.10 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.10 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。